KURN Kuros Biosciences AG

Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update

Kuros Biosciences AG / Key word(s): Annual Results
Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update

08.03.2024 / 07:00 CET/CEST

-    Company to host conference call and webcast on March 13, 2024, at 3pm CET/10am US EST

Schlieren (Zurich), Switzerland, March 8, 2024 – Kuros Biosciences (“Kuros” or “the Company”), a leader in next-generation bone graft technologies, today announced that it will report its full-year financial results and provide a corporate update on its business on March 13, 2024.  Following the announcement, the company will host a video conference call at 3pm CET/10am US EST to discuss the results. 

To register for the video call, click . 

For further information, please contact:

Kuros Biosciences AG 
Daniel Geiger
Chief Financial Officer
t: 7
e: 		 LifeSci Advisors 
Sandya von der Weid
Investors
t:
e: 

About Kuros Biosciences
Kuros Biosciences is on a mission to discover, develop and deliver innovative biologic fusion technologies. With locations in the United States, Switzerland and the Netherlands, the company is listed on the SIX Swiss Exchange. The company’s first commercial product, MagnetOsTM, is a unique advanced bone graft that has already been used across three continents and in 25,000 fusion surgeries. For more information on the company, its products and pipeline, visit .


End of Media Release
Language: English
Company: Kuros Biosciences AG
Wagistrasse 25
8952 Schlieren
Switzerland
Phone:
Fax:
E-mail:
Internet:
ISIN: CH0325814116
Valor: 32581411
Listed: SIX Swiss Exchange
EQS News ID: 1854131

 
End of News EQS News Service

1854131  08.03.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1854131&application_name=news&site_id=research_pool
EN
08/03/2024

Underlying

KURNKuros Biosciences AG

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kuros Biosciences AG

 PRESS RELEASE
Free
KURN Kuros Bioscienc...

Kuros Biosciences to share latest MagnetOs™ market impact and strategi...

Kuros Biosciences to share latest MagnetOs™ market impact and strategic priorities at Capital Market Day in Zürich     Kuros Biosciences to share latest MagnetOs™ market impact and strategic priorities at Capital Markets Day in Zürich Schlieren (Zürich), Switzerland, May 13, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies, is pleased to announce today’s Capital Markets Day on Tuesday, May 13, 2025, at 9am CEST, at the Hyatt Regency Zürich Airport, The Circle, Zürich, Switzerland. The event will also be available virtually via live webcast....

May 13, 2025 1 EN
Free Trial
KURN Kuros Bioscienc...

Kuros Biosciences AG: 1 director

A director at Kuros Biosciences AG sold 60,000 shares at 21.080CHF and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...

KURN KUROS BIOSCIENCES AG
04/23/25 April 23, 2025 1 EN
 PRESS RELEASE
Free
KURN Kuros Bioscienc...

Annual General Meeting of Kuros Biosciences approves all resolutions

Annual General Meeting of Kuros Biosciences approves all resolutions Annual General Meeting of Kuros Biosciences approves all resolutions Schlieren (Zurich), Switzerland, April 15, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, held its Annual General Meeting today. The Annual General Meeting approved the Annual Report, the Annual Financial Statements, and the Consolidated Financial Statements for the year 2024 and took note of the Reports of the Auditors. Shareholders granted discharge to the Board and the Executive Committee,...

April 15, 2025 1 EN
 PRESS RELEASE
Free
KURN Kuros Bioscienc...

Kuros Biosciences reports 82% year over year increase in sales in the ...

Kuros Biosciences reports 82% year over year increase in sales in the first three months of 2025 Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences reports 82% year over year increase in sales in the first three months of 2025 Financial & Operational Highlights Direct MagnetOs™ sales increased by 79% to USD 28.4 million in Q1 2025 (Q1 2024: USD 15.8 million)Total Medical Device sales rose by 82% to USD 28.8 million (Q1 2024: USD 15.8 million) with monthly revenue surpassing USD 10.0 million for the first timeTotal Group EBITDA reached USD 2.0 millio...

April 15, 2025 1 EN
 PRESS RELEASE
Free
KURN Kuros Bioscienc...

Kuros Biosciences grows sales to CHF 75.6 million for 2024

Kuros Biosciences grows sales to CHF 75.6 million for 2024 Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences grows sales to CHF 75.6 million for 2024 Financial Highlights Direct MagnetOs™ sales increased by 136% to CHF 74.8 million (2023: CHF 31.7 million)Total Medical Device sales rose by 125% to CHF 75.6 million (2023: CHF 33.6 million)Total Group EBITDA reached CHF 2.2 million (2023: EBITDA loss of CHF (5.9) million), including the impairment, the group ended in a net loss of CHF (4.3) millionTotal Group adjusted EBITDA amounted to CHF 9.0 millio...

March 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch